Research programme: triapine prodrug therapy - Vion
Latest Information Update: 04 Dec 2007
At a glance
- Originator Vion Pharmaceuticals
- Mechanism of Action Ribonucleotide reductase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 29 Mar 2001 Preclinical development for Cancer in USA (Unknown route)